ClinicalTrials.gg
TerminatedNCT03451253Updated Mar 23, 2023

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

An interventional study of amino acid mixture beverage and glucose-based sports drink in Inflammatory Bowel Diseases, Short Bowel Syndrome and Ileostomy - Stoma, sponsored by Entrinsic Bioscience Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Entrinsic Bioscience Inc. · Not applicable, Interventional, and Other

Why this study was terminated
Suboptimal accrual
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

Read the detailed description

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

02

Conditions studied

  • Inflammatory Bowel Diseases
  • Short Bowel Syndrome
  • Ileostomy - Stoma
03

In context

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 426 are open to participants now.

This study's enrollment of 7 is below the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Entrinsic Bioscience Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Colectomy with ileostomy

    a. Ileostomy alone with less than 30 cm of small bowel resected i. A diverting ileostomy is permitted

  2. Stable disease activity with no or mild inflammation felt not to significantly impact gastrointestinal (GI) output.
  3. Any of the following:

    1. Need for IV fluids >2x/month
    2. Intake of > 1.5 liters of oral fluid daily
  4. GI output of > 1.3 liters in a 24-hour period for three days each week during a 14 day screening period (does not need to be consecutive days)
  5. Stable doses of anti-diarrheal agents, octreotide or Gattex
  6. Stable doses of anti-inflammatory agents and/or antibiotics
  7. Willing to comply with study visits and assessments, including product intake.

Exclusion criteria

Exclusion:

  1. Chronic renal insufficiency (GFR) \< 40
  2. Significant chronic liver disease altering fluid balance
  3. Uncontrolled flare of inflammatory disease

    a. (Inflammation can be present but at a stable at least partly controlled level) b. An anticipated change in medication in the next 3 months i. May be included 8 weeks after changing medications if they are stable c. Anticipated gastrointestinal surgery in the subsequent 3 months i. May be included if they are 4 months out from surgery and stable

  4. Diabetes
  5. Use of Lactulose/Mannitol solution is
  6. Current Diagnosis of Cancer

    a. May be included if they are 4 or more months out from cancer therapy (i.e. chemotherapy, etc.)

  7. Aversion to the taste of enterade® or inability to take the product as instructed
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    amino acid mixture beverage

    amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.

    Other: amino acid mixture beverage

  • Active comparator
    glucose based sports drink

    glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.

    Other: glucose-based sports drink

Interventions

  • Otheramino acid mixture beverage

    commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.

    Also known as: enterade

  • Otherglucose-based sports drink

    Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.

    Also known as: Gatorade

06

What researchers measure

Primary outcomes

  1. GI output

    Change in GI output over a 24 hour period as the average of the 3 days every week for two different periods of 4 weeks

    Time frame: total 8 weeks

Secondary outcomes

  1. Fluid Balance

    Fluid balance - intake vs output

    Time frame: 8 weeks

  2. Tolerability of Drink

    Taste perception Survey

    Time frame: 8 weeks

  3. Quality of Life Index

    Inflammatory Bowel Disease Questionnaire (IBDQ)

    Time frame: 8 weeks

  4. Quality of Life Index

    SF-36 Questionnaire

    Time frame: 8 weeks

  5. Changes in Blood

    mm Hg

    Time frame: 8 weeks

  6. Changes in heart rate

    Beats per minute

    Time frame: 8 weeks

  7. Changes in Lactulose-Mannitol Test

    The standard test for leaky gut syndrome

    Time frame: 8 weeks

  8. Immune Response based on Cytokine Levels

    Time frame: 8 weeks

07

Study locations

3 sites
  • Brighan and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dartmouth-Hitchcock
    Nashua, New Hampshire 03062, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03451253
Lead sponsor
Entrinsic Bioscience Inc.
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Apr 12, 2018
Primary completion
Mar 23, 2021
Completion
Mar 23, 2021
Last update
Mar 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion